NPJ Precision Oncology Impact Factor 2024

NPJ Precision Oncology 2024 Impact Factor: 8.0

Imagine a sharpshooter’s crosshairs zeroing in on a tumor cell – that’s the vibe behind ​NPJ Precision Oncology​. Launched in late 2016, this open-access journal (a Nature Partner Journal) quickly carved out a niche in the exploding field of precision oncology. It’s not just about high-powered lab studies; NPJ Precision Oncology explicitly welcomes everything from genomic analyses to case reports and clinical briefs. This journal is meant to be right on target for cutting-edge cancer research.

What NPJ Precision Oncology Aims For？

NPJ Precision Oncology was conceived as a one-stop-shop for targeted cancer science.

The founding press release explains that precision oncology involves tailoring cancer care to each patient’s genetic profile. Editors highlighted that the journal would publish all aspects of this field – from basic molecular discoveries to early clinical trials, even case reports and commentaries. In other words, if you have an oddball patient case or a tiny “n=1” trial that reveals something about personalized therapy, NPJ Precision Oncology will consider it. This broad scope is intentional: its editors describe targeted therapy and immunotherapy as “the most exciting and active research areas in cancer”, and NPJ Precision Oncology is built to shine a light on those stories.

Beyond content type, the journal’s structure is streamlined. It’s fully open access (articles freely available), and backed by the Nature portfolio, so it follows high standards.

Review speed is famously fast: for instance, in 2022 the median time from submission to first decision was only 8 days, and by 2024 it was 10 days. That’s practically warp speed in academic publishing! The idea is that scientists can aim, shoot, and see their work published (or at least get feedback) without long delays.

The Scoreboard: Impact Factor and Other Metrics

Here’s a quick breakdown of its core metrics for 2024:

• Impact Factor: 8.0
• 5-Year Impact Factor: 8.0
• Immediacy Index: 1.9
• Eigenfactor Score: 0.00910
• Article Influence Score: 2.964
• SNIP (Source Normalized Impact per Paper): 1.541
• SJR (SCImago Journal Rank): 3.370

What do these numbers mean in real terms? Think of the Impact Factor as an average citation score—on average, each article published in the last two years was cited 8 times. That’s quite strong for a niche oncology journal. The Immediacy Index tells us NPJ’s articles are often cited within the same year of publication—meaning its work gets noticed fast. The Eigenfactor and Article Influence Score add more nuance by considering the quality and breadth of those citations across disciplines.

Still, it’s worth remembering: no single number tells the whole story. Nature Portfolio itself notes (in line with the DORA declaration) that metrics like JIF can be influenced by a few highly cited articles. But in NPJ Precision Oncology’s case, the consistency across metrics speaks for itself.

SCImago further confirms its standing. With an ​SJR of 3.370​, the journal ranks firmly in ​Q1​—the top 25% of all oncology journals. Its h-index currently stands at ​46​, meaning at least 46 of its papers have been cited 46 times or more. In short: npj Precision Oncology isn’t just scoring citations—it’s producing sustained, influential work that keeps shaping the field.

Beyond the IF: Reads, Speed, and Other Numbers

While the impact factor grabs headlines, npj Precision Oncology demonstrates excellence across multiple metrics. Reader engagement is one such standout: full-text article downloads surged from 543,000 in 2022 to over 1.6 million in 2024. That’s a massive reach, highlighting the journal’s relevance in both research and clinical communities.

Engagement beyond academia also matters. In 2024, npj Precision Oncology accumulated ​2,182 Altmetric mentions​, including coverage in news outlets, X (formerly Twitter), and blogs. These numbers suggest its research is not only read but discussed and shared — a sign of growing influence across scientific and public spheres.

Fast Decisions, Faster Publishing

For authors, submission speed is crucial. In 2024, the median time from submission to first editorial decision was just 10 days. That’s significantly faster than the industry average. Compare that with journals that may take weeks just to acknowledge a submission — ​npj Precision Oncology​’s responsiveness stands out.

Even from submission to acceptance (including peer review and revisions), the journal maintains efficiency, with a ​median time of 187 days​. In the world of oncology research, where findings can be time-sensitive, speed doesn’t just benefit authors — it accelerates the entire scientific dialogue.

More Than Metrics: A Mission-Driven Journal

Metrics matter, but npj Precision Oncology positions itself as more than just a numbers game. From its launch, the editorial board emphasized building “a global community that advances the field of precision oncology” (editorial). That means prioritizing research that matters, including original studies, case reports, and translational breakthroughs.

One More Tool in Your Precision Toolkit: PubMed.ai’s Research Report

Reading high-impact journals like npj Precision Oncology is exciting—no doubt. But let’s be honest: staying on top of the literature, connecting ideas, and turning that into structured research writing? That’s a beast of a task.

This is where PubMed.ai steps in. If you’re already combing through PubMed.ai for related papers, you might want to try our Research Report feature—it’s kind of a hidden gem. What it does is pretty clever: based on your ​search activity​, PubMed.ai will:

• Understand your research topic and scope
• Find additional relevant PubMed literature
• Generate a structured academic report with the standard format: Abstract, Introduction, Methods, Results, and Conclusion
• Package the report as both ​PDF and Word documents​, including full references
• Email it directly to your inbox so you can start citing or editing immediately.

It’s like having a research assistant who never sleeps (and never misses a citation). Especially when you’re exploring dense, fast-moving areas like precision oncology, tools like this can shave hours off your workflow—and give you something tangible to work from.

So, whether you’re summarizing a batch of npj Precision Oncology case reports or preparing your next grant draft, PubMed.ai’s Research Report gives you a head start. Think of it as precision reading—for the age of precision medicine.

FAQs

What is the NPJ Precision Oncology Impact Factor?

NPJ Precision Oncology's 2024 impact factor is 8.0 according to Journal Citation Reports.

Does NPJ Precision Oncology publish case reports?

Yes. Unlike many high-impact journals that focus only on large trials or reviews, NPJ Precision Oncology explicitly includes case reports among its article types. The founding editors noted that the journal will publish “important single subject clinical trials [and] rare responder studies” along with other formats. This means if you have a unique patient case illustrating precision therapy or an unusual molecular finding, NPJ Precision Oncology is a suitable venue (and it’s open access).

Is npj Precision Oncology a good journal?

Yes, npj Precision Oncology is widely regarded as a reputable and high-quality journal in the field of cancer research. As part of the Nature Portfolio, it maintains rigorous peer-review standards and offers open access to all articles, making research widely accessible. Its ​2024 impact factor is 8.0​, placing it firmly in the top quartile (Q1) of oncology journals. The journal is especially valued for publishing a wide range of content—from cutting-edge genomic studies to clinical case reports—and for its rapid editorial turnaround (about 10 days to first decision). For researchers in personalized or targeted cancer therapy, it’s considered a go-to source for credible and impactful findings.

Disclaimer:
This AI-assisted content is intended for academic reference and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult qualified healthcare professionals regarding any medical condition or treatment decisions. All risks arising from reliance on this content are borne by the user, and the publisher assumes no responsibility for any decisions or actions taken.